The present active ingredient in this medicine; Tranexamic Acid inhibits the activation of plasminogen and prevents the breakdown of fibrin clots. This reduces excessive bleeding by promoting clot stability.

• This medicine is injected intravenously under the supervision of healthcare professionals.
• Dose and duration depend on the medical condition of the patients. .

• It is important to regularly monitor signs of thrombosis in patients with a medical history of clotting disorders.
• It should be cautiously among the patient suffering from kidney disease or those at a risk of hematuria.
• It should not be taken by the patients with active intravascular clotting.

• It helps control excessive bleeding in heavy menstrual periods, surgeries, and trauma.
• Helps in managing hereditary angioedema.

• allergic reactions
• nausea
• dizziness
• vomiting
• diarrhea
• renal dysfunction
• thromboembolic events
• visual disturbances